Drug Type Trispecific antibody |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), FcγR modulators(FcγR modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Hinge Bio, Inc.Startup |
Active Organization Hinge Bio, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Preclinical | US | Hinge Bio, Inc.Startup | 08 Apr 2024 |
B-Cell Lymphoma | Preclinical | US | Hinge Bio, Inc.Startup | 22 Mar 2024 |